5 Coding Assistants Reviving Stalled Projects—And Changing Developer Mindsets
Discover how coding assistance tools are empowering developers and reviving stalled projects in software development.
Life Savings Vanish: A Fidelity Glitch Exposes Crypto’s Dark Side
The Fidelity glitch shows systemic issues in financial technology integration, raising urgent questions for crypto investors.
America’s Geothermal Revolution: A $150 Billion Hidden Energy Potential
Discover how geothermal energy could reshape the U.S. energy landscape, offering 150 GW of clean power and reshaping investment strategies.
10 Crucial USB Insights from 2022 That Could Transform Tech Security
Discover how USB vulnerabilities threaten cybersecurity and which insights can transform tech security strategies in 2022.
America’s Geothermal Breakthrough Could Unlock 150 GW of Clean Energy Potential
Discover how geothermal energy could reshape America’s clean energy future, potentially supplying 20% of the nation’s electricity by 2050.
How OpenAI’s Privacy Filter Could Change Data Monetization Forever
OpenAI’s Privacy Filter empowers users with data control, challenging traditional data monetization strategies.
OpenAI’s Privacy Filter: A Game Changer for Corporate Data Security
OpenAI’s Privacy Filter promises up to 90% reduction in data leaks, redefining corporate data security standards amid AI adoption.
Only 2 New Alzheimer’s Drugs Approved in 20 Years: What’s Going Wrong?
Despite $2.6 billion in funding, only 2 new Alzheimer’s drugs were approved in two decades, highlighting systemic failures in biotech.
Only 1 Drug Approved in 20 Years: What’s Holding Back Alzheimer’s Research?
By Dana Kim, Crypto Markets Analyst Last updated: April 26, 2026 Only 1 Drug Approved in 20 Years: What’s Holding Back Alzheimer’s Research? Over the past 20 years, only one drug for Alzheimer’s disease has gained FDA approval, a shocking figure given the escalating costs and urgent need for effective treatments. The financial intensity of … Read more
Only 4 New Alzheimer’s Drugs in 20 Years? Here’s Why That’s a Crisis
Explore the alarming stagnation in Alzheimer’s drug approvals and the systemic flaws hindering breakthroughs in treatment.